- Inspire Medical’s operating expense for Q4 was $171.8 million, which is an 11% increase year-over-year, but lower than the estimated $180.5 million.
- Earnings per share (EPS) reached $1.15 in Q4, compared to 49 cents in the previous year and exceeded the estimate of 73 cents.
- Cash and cash equivalents stood at $150.2 million, a 19% decrease from the previous year and below the estimated $234.8 million.
- Revenue increased by 25% year-over-year to $239.7 million, surpassing the estimate of $237 million.
- The company has introduced its full-year 2025 diluted net income per share guidance, ranging from $2.10 to $2.20.
- Revenue guidance for the full year 2025 remains unchanged at $940 million to $955 million, reflecting a growth expectation of 17% to 19% compared to 2024.
- The gross margin for the full year is anticipated to be between 84% and 86%.
- Inspire Medical is optimistic about continuing its strong performance in 2025, supported by the launch of Inspire V.
- Analyst recommendations include 14 buys and 5 holds, with no sells.
Inspire Medical Systems Inc on Smartkarma
Analyst coverage on Inspire Medical Systems Inc on Smartkarma has been positive, with Baptista Research providing insightful research reports on the company’s recent performance and growth prospects. In one report titled “Inspire Medical Systems: Is The New Inspire V System A Game Changer? – Major Drivers,” Inspire’s strong third-quarter results, showcasing significant revenue growth and improved profitability, were highlighted. The company’s revenue surged by 33% in the third quarter of 2024, primarily driven by the increased adoption of Inspire therapy, expansion into new implanting centers, and growth in U.S. sales territories.
Another report by Baptista Research, “Inspire Medical Systems: Expanded Market Penetration Catalyzing Growth! – Major Drivers,” emphasized the company’s achievements in the second quarter of 2024. Inspire Medical Systems treated over 75,000 patients with its innovative therapy for obstructive sleep apnea, marking a significant milestone. Baptista Research delved into various factors influencing the company’s future stock price and conducted an independent valuation using a Discounted Cash Flow methodology, reflecting optimism about Inspire’s market penetration and growth trajectory.
A look at Inspire Medical Systems Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Inspire Medical Systems Inc appears to have a positive long-term outlook. With high scores in Growth and Resilience, the company is positioned well for future expansion and shows strong ability to withstand challenges. Its focus on developing implantable neurostimulation systems to treat obstructive sleep apnea positions it in a niche market with potential for growth. Despite lower scores in Value and Dividend, the higher scores in Growth and Resilience indicate a promising trajectory for the company.
Inspire Medical Systems Inc, a medical technology company based in the United States, specializes in neurostimulation systems for obstructive sleep apnea treatment. With impressive Smartkarma Smart Scores of 4 for Growth and 5 for Resilience, the company demonstrates a strong potential for long-term success. Although Value and Dividend scores are not as high, the company’s innovative solutions and focus on a specific healthcare niche indicate a resilient and growing business model moving forward.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
